NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of CTO Realty Growth, Inc.  (“CTO” or the “Company”) (NYSE: CTO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CTO and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On June 25, 2025, W ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of The J.M. Smucker Company regarding potential securities fraud or unlawful business practices by the company and its officers [1] Company Performance - On November 7, 2023, Smucker announced the acquisition of Hostess Brands for approximately $5.5 billion, with $2.4 billion recorded as goodwill in the Sweet Baked Snacks segment [3] - On February 27, 2025, Smucker reported disappointing Q3 2025 results, including an 8% decrease in comparable net sales in the Sweet Baked Snacks segment, a $794 million impairment charge related to goodwill, a $208 million impairment charge for the Hostess Brand trademark, and a $268 million loss on the disposal of the Voortman business [3] - On June 10, 2025, Smucker reported further disappointing Q4 2025 results, with a 14% decrease in comparable net sales in Sweet Baked Snacks, an additional $867 million impairment charge related to goodwill, and an additional $113 million impairment of the Hostess Brand trademark [3] - The company updated its 2026 financial plan to reflect decreased net sales in the Sweet Baked Snacks segment, citing sustained underperformance since the acquisition [3] - Following the announcement of Q4 results, Smucker's stock price fell by $17.44 per share, or 15.59%, closing at $94.41 per share [3]

Core Viewpoint - Pomerantz LLP is investigating claims related to potential securities fraud or unlawful business practices involving Necessity Retail REIT, Inc. following its acquisition by Global Net Lease, Inc. [1][2] Group 1: Investigation Details - The investigation focuses on whether Necessity Retail and certain officers or directors engaged in securities fraud or other unlawful business practices [2] - Investors who received shares of Global Net Lease in connection with the merger on September 12, 2023, are encouraged to contact Pomerantz LLP [1] Group 2: Financial Projections and Market Performance - The Offering Materials for the merger projected Adjusted Funds From Operations (AFFO) for the combined company to be $399.8 million for 2024 and $409.0 million for 2025 [4] - Since the merger date, Global Net Lease's share price has declined by over 33% [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Mereo BioPharma Group plc and its officers or directors [1] Group 1: Company Developments - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced progress in the Phase 3 Orbit study for UX143 (setrusumab) in treating osteogenesis imperfecta, with a final analysis expected by the end of the year [3] - Following this announcement, Mereo's ADR price dropped by $1.25, or 42.52%, closing at $1.69 per share on July 10, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered numerous multimillion-dollar damages for class members over its 80-year history [4]

Core Insights - Simulations Plus, Inc. is under investigation for potential securities fraud and unlawful business practices involving its officers and directors [1] - The company reported disappointing financial results for Q3 2025, with sales of $20.4 million, a net loss of $67.3 million, and a diluted loss per share of $3.35, significantly down from a net income of $3.1 million and earnings per share of $0.15 in Q3 2024 [3] - Following the financial report, Simulations Plus's stock price dropped by $4.50, or 25.76%, closing at $12.97 per share [4] - The company revised its fiscal 2025 adjusted earnings guidance down to a range of $0.93 to $1.06, from a previous estimate of $1.07 to $1.20 [3] - A restructuring initiative was initiated in June 2025, which includes workforce reductions and cost-cutting measures aimed at improving operational efficiency [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving GSK plc and its officers or directors, following a negative FDA advisory vote impacting the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of GSK plc and is urging them to contact the firm regarding the investigation [1]. - The investigation focuses on whether GSK and its executives have engaged in securities fraud or other illegal activities [1]. Group 2: Stock Market Reaction - On July 17, 2025, GSK announced that the FDA Oncologic Drugs Advisory Committee voted against the benefit/risk profile of Blenrep at the proposed dosage [3]. - Following this announcement, GSK's American Depositary Receipt (ADR) price dropped by $1.81, or 4.73%, closing at $36.47 per share [3]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4]. - The firm has a track record of recovering significant damages for class members over its 80-year history [4].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Nutex Health Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Blue Orca Capital issued a short report alleging that Nutex faces litigation risk due to its relationship with HaloMD, which is involved in a fraudulent scheme against insurance companies [2] - Following the release of the Blue Orca report, Nutex's stock price dropped by $11.18 per share, a decrease of 10.05%, closing at $100.01 per share on July 22, 2025 [3] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud [4]

Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by The J.M. Smucker Company and its officers or directors [1] - Smucker's acquisition of Hostess Brands for approximately $5.5 billion has led to significant financial challenges, including substantial impairment charges and declining sales in the Sweet Baked Snacks segment [2] Financial Performance - On November 7, 2023, Smucker completed the acquisition of Hostess Brands, recording $2.4 billion as goodwill in the Sweet Baked Snacks segment [2] - Q3 2025 results showed an 8% decrease in comparable net sales for Sweet Baked Snacks, alongside a $794 million impairment charge related to goodwill and a $208 million impairment charge for the Hostess Brand trademark [2] - Q4 2025 results revealed a further 14% decrease in comparable net sales for Sweet Baked Snacks, with an additional $867 million impairment charge for goodwill and a $113 million impairment charge for the Hostess Brand trademark [2] - Following these disappointing results, Smucker's stock price dropped by $17.44 per share, or 15.59%, closing at $94.41 per share on June 10, 2025 [2] Strategic Outlook - The company has revised its 2026 financial plan, indicating decreased net sales in the Sweet Baked Snacks segment due to sustained underperformance since the acquisition [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ultragenyx Pharmaceutical Inc. and its officers or directors [1] Group 1: Company Developments - On July 9, 2025, Ultragenyx and Mereo BioPharma Group plc announced progress in the Phase 3 Orbit study for UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta, with a final analysis expected around the end of the year [3] - Following the announcement, Ultragenyx's stock price dropped by $10.41 per share, or 25.11%, closing at $31.04 per share on July 10, 2025 [3] Group 2: Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Barnes & Noble Education, Inc. is under investigation for potential securities fraud and unlawful business practices, which has led to a significant drop in its stock price following the announcement of a delay in its annual report due to accounting issues [1][3][4]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of investors regarding potential securities fraud by Barnes & Noble and its officers or directors [1]. - The investigation is focused on how the costs of digital sales were recorded, with early findings suggesting that accounts receivable may have been overstated by up to $23 million [3]. Group 2: Financial Impact - Following the announcement of the investigation and the delay in the annual report, Barnes & Noble's stock price fell by $2.36 per share, representing a 21.02% decrease, closing at $8.87 per share on July 21, 2025 [4]. Group 3: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5].